100 related articles for article (PubMed ID: 3334664)
1. Cytokinetic-based versus conventional chemotherapy in metastatic breast cancer: a randomized study.
Conte PF; Rubagotti A; Falcone A; Gardin G; Nicolin A; Pronzato P; Rosso R; Amadori D; Gentilini P; Sismondi P
Chemioterapia; 1987 Jun; 6(2 Suppl):712-3. PubMed ID: 3334664
[No Abstract] [Full Text] [Related]
2. [Chemotherapy protocol with taxol increase survival by 31 percent].
Krankenpfl J; 2002; 40(7-9):226. PubMed ID: 12514866
[No Abstract] [Full Text] [Related]
3. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
Ost E; Illiger HJ
Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
[No Abstract] [Full Text] [Related]
4. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
Tamura K
Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
[No Abstract] [Full Text] [Related]
5. Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial.
Marschner N; Kreienberg R; Souchon R; Räth U; Eggeling B; Voigtmann R; Ruffert K; Schütte M; Ammon A; Kesztyüs T
Semin Oncol; 1994 Feb; 21(1 Suppl 1):10-6. PubMed ID: 8153652
[No Abstract] [Full Text] [Related]
6. Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial.
Kümmel S; Krocker J; Kohls A; Breitbach GP; Morack G; Budner M; Blohmer JU; Lichtenegger W; Elling D
Crit Rev Oncol Hematol; 2006 May; 58(2):166-75. PubMed ID: 16387512
[TBL] [Abstract][Full Text] [Related]
7. Epirubicin versus mitoxantrone in combination chemotherapy for metastatic breast cancer.
Pavesi L; Preti P; Da Prada G; Pedrazzoli P; Poggi G; Robustelli della Cuna G
Anticancer Res; 1995; 15(2):495-501. PubMed ID: 7763029
[TBL] [Abstract][Full Text] [Related]
8. Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: results of a randomized cooperative trial.
Conte PF; Pronzato P; Rubagotti A; Alama A; Amadori D; Demicheli R; Gardin G; Gentilini P; Jacomuzzi A; Lionetto R
J Clin Oncol; 1987 Mar; 5(3):339-47. PubMed ID: 3546611
[TBL] [Abstract][Full Text] [Related]
9. [Sequential combination chemotherapy in metastatic cancer of the breast].
Leone BA; Rabinovich MG; Strauss E; Arévalo E
Medicina (B Aires); 1984; 44(1):15-22. PubMed ID: 6549523
[No Abstract] [Full Text] [Related]
10. Chemotherapy and concomitant irradiation in inflammatory breast cancer.
Tubiana-Mathieu N; Lejeune C; Bonnier P; Genet D; Adjadj DJ; Berda JF; Muracciole X; Delaby F; Clavere P; Benyoub A; Rhein B; Juin B; Piana L
Anticancer Res; 2001; 21(4B):3061-7. PubMed ID: 11712811
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
[TBL] [Abstract][Full Text] [Related]
12. [Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil].
Ruffert K
Zentralbl Chir; 1998; 123 Suppl 5():156-8. PubMed ID: 10063603
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
[TBL] [Abstract][Full Text] [Related]
14. Commentary on PBT-1 study of high-dose consolidation versus standard therapy in metastatic breast cancer.
Livingston R; Crowley J
J Clin Oncol; 1999 Nov; 17(11 Suppl):22-4. PubMed ID: 10630257
[No Abstract] [Full Text] [Related]
15. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
[TBL] [Abstract][Full Text] [Related]
16. Multiple drug intensification after cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) induction in metastatic breast cancer: a Southeastern Cancer Study Group phase II trial.
Vogel CL; Raney M; Carpenter J
Cancer Treat Rep; 1987 Dec; 71(12):1271-3. PubMed ID: 3690536
[No Abstract] [Full Text] [Related]
17. Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.
Ventura GJ
J Clin Oncol; 2005 Apr; 23(12):2873; author reply 2873-4. PubMed ID: 15838014
[No Abstract] [Full Text] [Related]
18. Successful pregnancy outcome with 5-flurouracil, epirubicin, cyclophosphamide chemotherapy, and hemostatic radiotherapy with abdominal shielding for metastatic invasive intraductal breast carcinoma.
Sharma JB; Pushparaj M; Kumar S; Roy KK; Raina V; Malhotra N
Arch Gynecol Obstet; 2009 Mar; 279(3):415-7. PubMed ID: 18642013
[TBL] [Abstract][Full Text] [Related]
19. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
[TBL] [Abstract][Full Text] [Related]
20. Sclerotic and retracted supravenous hyperpigmentation associated with combination chemotherapy for metastatic breast carcinoma.
Chen GY; Lee JY; Chen WC
Br J Dermatol; 2005 Jun; 152(6):1383-5. PubMed ID: 15949026
[No Abstract] [Full Text] [Related]
[Next] [New Search]
